1. Scrip
  2. >>Business
  3. >>Earnings

Novartis Chief: Good Things Come To Those Who Wait

 
• By Eleanor Malone

In the company’s third-quarter conference call, Novartis CEO Joe Jimenez admitted that generic competition to its blockbuster Gleevec will continue to drag on the company in 2017. However, he touted a pipeline of 12 potential blockbusters and restructuring efforts over the past three years as evidence that the company will be positioned for growth from 2018.

Novartis AG is headed for an uptick but not for more than a year: that was the message from CEO Joe Jimenez as the company reported its third-quarter results. “The future of this company is not about 2017: it’s about 2018, 2019, 2020,” said Jimenez, responding to questioning by analysts on specific challenges the firm faces, notably the under-performance of its Alcon Inc. eye care division and the ongoing ramp-up in generic competition to its blockbuster drug Gleevec (imatinib), which will face European genericization from December 2016 on top of the existing competition in the US.

Executives acknowledged that the return to growth of Alcon, once promised for this year, will now be slower in coming,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

PTC Projects Confidence In Sephience Launch With Royalty Buyback

 
• By Manas Mishra

The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

 
• By Mandy Jackson

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

More from Business

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By Vibha Ravi

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis